Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase

  title={Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase},
  author={Alfredo Ram{\'i}rez and Andr{\'e} Heimbach and Jan Gr{\"u}ndemann and Barbara Stiller and Daniel J. Hampshire and L. Pablo Cid and Ingrid Goebel and Ammar Fayez Mubaidin and Abdul-Latif Wriekat and Jochen Roeper and A N Al-din and Axel M. Hillmer and Meliha Karsak and Birgit Liss and Christopher Geoffrey Woods and Maria Isabel Behrens and Christian Kubisch},
  journal={Nature Genetics},
Neurodegenerative disorders such as Parkinson and Alzheimer disease cause motor and cognitive dysfunction and belong to a heterogeneous group of common and disabling disorders. [] Key Method Here, we describe loss-of-function mutations in a previously uncharacterized, predominantly neuronal P-type ATPase gene, ATP13A2, underlying an autosomal recessive form of early-onset parkinsonism with pyramidal degeneration and dementia (PARK9, Kufor-Rakeb syndrome). Whereas the wild-type protein was located in the…
Mutations in the ATP13A2 Gene and Parkinsonism: A Preliminary Review
It is proposed that a single pathway whereby ATP13A2 mutations may contribute to NCLs and Parkinsonism is proposed, and how studies of mutations in this gene may provide new insights into PD pathogenesis and identify potential therapeutic targets is highlighted.
The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms
A new understanding is provided of the role that ATP13A2 plays in the development of PD and a therapeutic target is identified that may ameliorate α‐synuclein accumulation and lysosomal and mitochondrial dysfunction in Parkinson's disease.
Pathogenic mutations in Parkinson disease
It is suggested that deficits in mitochondrial function, oxidative and nitrosative stress, the accumulation of aberrant or misfolded proteins, and ubiquitin‐proteasome system (UPS) dysfunction may represent the principal molecular pathways that commonly underlie the pathogenesis of Parkinson disease.
Endolysosomal Dysfunction in Parkinson Disease: The Role of Disease Mutations in ATP13A2 and LRRK2.
It is shown that Atp13a2 null mice develop age-related motor abnormalities that are preceded by neuropathological changes including gliosis, accumulation of ubiquitinated protein aggregates, lipofuscinosis, and lysosomal abnormalities.
Deficiency of ATP13A2 Leads to Lysosomal Dysfunction, α-Synuclein Accumulation, and Neurotoxicity
It is reported that loss of ATP13A2 in human fibroblasts from patients with Kufor–Rakeb syndrome or in mouse primary neurons leads to impaired lysosomal degradation capacity, which results in accumulation of α-synuclein and toxicity in primary cortical neurons.
α-Synuclein-Independent Histopathological and Motor Deficits in Mice Lacking the Endolysosomal Parkinsonism Protein Atp13a2
It is shown that loss of ATP13A2 causes a specific protein trafficking defect, and that Atp13a2 null mice develop age-related motor dysfunction that is preceded by neuropathological changes, including gliosis, accumulation of ubiquitinated protein aggregates, lipofuscinosis, and endolysosomal abnormalities.
Molecular Genetics of Parkinsonism
The knowledge of the pathogenesis of Parkinson disease at a molecular level will have important implications for the development of individual therapeutic strategies to prevent disease progression andome-wide association studies provide a powerful tool to identify low penetrance at-risk alleles.
Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration
It is shown that PD-linked mutations in ATP13A2 lead to several lysosomal alterations in PD patient-derived fibroblasts, including impaired lyssomal acidification, decreased proteolytic processing of lysOSomal enzymes, reduced degradation of lYSosomal substrates, and diminished lysoomal-mediated clearance of autophagosomes.
The Roles of ATP13A2 Gene Mutations Leading to Abnormal Aggregation of α-Synuclein in Parkinson’s Disease
This article discusses lysosomal autophagy inhibition and the molecular mechanism of abnormal α-synuclein accumulation caused by decreased levels and dysfunction of the ATP13A2 protein in lysOSomes, and provides a new direction for future research on the pathogenesis and therapeutic targets for ATP13 a2 gene-related PD from the perspective of ATP 13A2 gene mutations and abnormal aggregation of α- synuclein.
Update on the genetics of Parkinson's disease
  • T. Gasser
  • Biology
    Movement disorders : official journal of the Movement Disorder Society
  • 2007
Evidence is emerging that at least some of these genes may play a direct role in the etiology of the common sporadic form of Parkinson's disease, and the cellular pathways identified in rare monogenic variants of the disease also shed light on the molecular pathogenesis in typical sporadic PD.


Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
The identification of two homozygous mutations affecting the PINK1 kinase domain in three consanguineous PARK6 families provide a direct molecular link between mitochondria and the pathogenesis of PD.
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Mutations in the newly identified gene appear to be responsible for the pathogenesis of Autosomal recessive juvenile parkinsonism, and the protein product is named ‘Parkin’.
α-Synuclein Is Degraded by Both Autophagy and the Proteasome*
It was found that not only is α-synuclein degraded by the proteasome, but it is also degraded by autophagy, which merits consideration as a potential therapeutic for Parkinsons disease, as it is designed for chronic use in humans.
Molecular Pathways of Neurodegeneration in Parkinson's Disease
Strategies aimed at restoring complex I activity, reducing oxidative stress and α-synuclein aggregation, and enhancing protein degradation may hold particular promise as powerful neuroprotective agents in the treatment of PD.
DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism
Evidence from genetic studies on the yeast DJ-1 homologue, and biochemical studies in murine and human cell lines, suggests a role forDJ-1 as an antioxidant and/or a molecular chaperone, and this will lead to a better understanding of the pathogenesis of DJ- 1-related and common forms of Parkinson’s disease.
Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway
It is demonstrated that cells are capable of clearing preformed α-synuclein aggregates via the lysosomal degradation pathway, and it is suggested that enhancing lysOSomal function may be a potential therapeutic strategy to halt or even prevent the pathogenesis of Parkinson's disease and other Lewy body diseases.
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
It is found that wild-type α-synuclein was selectively translocated into lysosomes for degradation by the chaperone-mediated autophagy pathway, which may underlie the toxic gain-of-function by the A53T and A30P mutants.
Parkinsonism among Gaucher disease carriers
Observations indicate that mutant glucocerebrosidase, even in heterozygotes, may be a risk factor for the development of parkinsonism, and will provide insights into the genetics, pathogenesis, and treatment of Parkinson disease.
Kufor Rakeb Disease: Autosomal recessive, levodopa‐responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia
Several new features were identified, including facial‐faucial‐finger mini‐myoclonus, visual hallucinations, and oculogyric dystonic spasms inKufor Rakeb disease, and a locus on chromosome 1p36 that was previously assigned PARK9 was identified.
Pallido‐pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor‐Rakeb syndrome
It is suggested that an unusual neurological syndrome in an Arab family with five affected siblings probably represents a new syndrome which is closely related but not identical to the pallido‐pyramidal syndrome.